Oregovomab

Oregovomab is a monoclonal antibody used in the treatment of ovarian cancer. It targets the antigen CA-125, which is often elevated in ovarian cancer patients. Oregovomab is designed to stimulate the patient's immune system to recognize and attack cancer cells expressing CA-125.

Mechanism of Action

Oregovomab binds to the CA-125 antigen, which is present on the surface of ovarian cancer cells. This binding event is thought to activate the immune system, particularly T-cells, which then learn to recognize and kill cells expressing CA-125. This approach is part of a broader category of cancer therapy known as immunotherapy, which aims to boost the body's own immune system to fight cancer.

Clinical Trials

Oregovomab has been evaluated in several clinical trials. Early phase trials focused on assessing its safety and optimal dosing strategies. Subsequent trials have evaluated its efficacy, often comparing it with standard chemotherapy treatments or in combination with other therapeutic agents. The results of these trials have been mixed, with some showing promise in extending survival or delaying disease progression, while others have not demonstrated significant benefits.

Usage

The use of oregovomab is typically considered in cases of advanced ovarian cancer where traditional therapies have failed or as part of a clinical trial setting. Its administration involves intravenous infusions, and the treatment regimen can vary depending on the specific clinical trial or treatment protocol.

Side Effects

As with many cancer treatments, oregovomab can cause side effects. These may include flu-like symptoms such as fever, chills, and fatigue, which are common to treatments that stimulate the immune system. More severe immune-related adverse effects can also occur, although they are less common.

Current Status

As of the last update, oregovomab is not widely used outside of clinical trials. Research is ongoing to better understand its potential role in ovarian cancer treatment, including its use in combination with other therapies.

See Also

• Cancer immunotherapy
• Ovarian cancer
• Monoclonal antibodies

   This article is a medical stub. You can help WikiMD by expanding it!